Cargando…
Funding innovation for treatment for rare diseases: adopting a cost-based yardstick approach
BACKGROUND: Manufacturers justify the high prices for orphan drugs on the basis that the associated R&D costs must be spread over few patients. The proliferation of these drugs in the last three decades, combined with high prices commonly in excess of $100,000 per patient per year are placing a...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832748/ https://www.ncbi.nlm.nih.gov/pubmed/24237605 http://dx.doi.org/10.1186/1750-1172-8-180 |